CARCINOGENESIS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2019-08-14 半瓶不动满瓶摇

慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表::
我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表:
我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结

路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结

218 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2025-03-24 ms2000001433009307 来自山西省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的

12 0

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2022-02-15 1221c8e5m44(暂无昵称)

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：小RNA
经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。

6 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2024-12-07 147e4799m34暂无昵称来自浙江省

偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学
经验分享：两个月了还没送外审，太慢。。。

29 0

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2024-05-03 ms9000001087203106 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。

101 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2024-05-03 ms9000001087203106 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。
18-Mar-2024： Submitted
30-Mar-2024：Major revision
15-Apr-2024: 大修修回
22-Apr-2024：Accept upon Revision（小修）
29-Apr-2024 ：小修修回
30-Apr-2024：Accept
速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！

110 0

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2022-12-17 ms5000001856769052 来自北京

请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊

148 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2023-12-03 ms5000000338699661 来自天津

请问接收article吗

116 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2024-01-03 羊0 来自福建省

投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。

118 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=574806, encodeId=fec55e480608, content=慢慢投下来的，往下投过oncogene，cancer letters，到小cdd，一直被秒拒，不送外审，很悲剧，也请了发nature的专家看过，觉得6分问题不大，结果还是一直被拒，估计老外对这一块不感兴趣，直到这个杂志，才外审，小修接受。路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结林申申 2019-08-12 00:00:00 发表: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, beContent=路过人间 2019-08-12 发表:: 我去从cancer research一点点下来呢，还是直接投这个杂志？有点纠结, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27631958520, createdName=半瓶不动满瓶摇, createdTime=Wed Aug 14 00:00:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257493, encodeId=d2e9225e4935c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：投稿3天就送了外审，做的生信分析结合一些表型的实验验证，外审了不到一个月，让小修，小修给了3个月时间，我们一个月就送回去了，二审10天左右就接受了，感觉效率还是蛮不错的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1409294259, createdName=ms2000001433009307, createdTime=Mon Mar 24 10:47:47 CST 2025, time=2025-03-24, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1193505, encodeId=4975119350540, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：小RNA 经验分享：2021.9.28 submitted 2021.9.30 Under Review (编辑手里评估) 2021.9.30 Under review (外审) 2021.10.25 Awaiting decision 2021.10.30 Major revision 2021.11.11 submitted 2021.11.11 Under review 2022.1.11 Awaiting decision 2022.1.13 Accept upon revision 2022.1.17 submitted 20221.27 Accept 总体来说，审稿二审比较慢，一审大都1个月左右，审稿意见比较专业，会得到比较好的意见进行修改，接收后很快就可以挂网上了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Tue Feb 15 10:10:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241273, encodeId=2ee422412e338, content=偏重的研究方向：肿瘤;肿瘤转移;肿瘤分子生物学 经验分享：两个月了还没送外审，太慢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat Dec 07 20:41:19 CST 2024, time=2024-12-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2201590, encodeId=e00b2201590b4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：有幸刚中1篇，这杂志感觉效率很高，投稿1周就开始审稿，3周给了大修，审稿人整体对文章满意，编辑很严谨，对图表要求很细致，感觉像老牌杂志的风格。对中国人友好，速度快，比某些漂亮国杂志更值得推荐。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 12:50:53 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201614, encodeId=a5b3220161499, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：从cancer research, oncogene, cancer letters等10个杂志一路受挫，最后投的这个杂志。 18-Mar-2024： Submitted 30-Mar-2024：Major revision 15-Apr-2024: 大修修回 22-Apr-2024：Accept upon Revision（小修） 29-Apr-2024 ：小修修回 30-Apr-2024：Accept 速度没有评论中说的那么慢，反而速度惊人，可能是以前速度慢吧？因为我的文章数据量很大，而且也严谨，主编看了觉得不错，反应很积极。审稿人的意见也很nice,没有补实验，编辑很仔细，对图表要求很细。整体来说，如果发不了1区的杂志，这个老牌杂志还是可以考虑的，中国人友好。希望能重归5分！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=567e6155028, createdName=ms9000001087203106, createdTime=Fri May 03 13:45:43 CST 2024, time=2024-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2106449, encodeId=61242106449a4, content=请问各位大神，这个杂志怎么看有没有送外审啊，under review，ED: Not Assigned半个月了，啥意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b6a8289282, createdName=ms5000001856769052, createdTime=Sat Dec 17 12:33:31 CST 2022, time=2022-12-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172722, encodeId=7f0421e2722f3, content=请问接收article吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf318642608, createdName=ms5000000338699661, createdTime=Sun Dec 03 19:01:57 CST 2023, time=2023-12-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2178966, encodeId=c3ef21e8966ef, content=投稿后不到一周送审，一个多月后拒稿，效率不错，重新投其他期刊，可惜了，今年降三区。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b35438089, createdName=羊0, createdTime=Wed Jan 03 10:06:00 CST 2024, time=2024-01-03, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=484187, encodeId=b8e748418ebb, content=三天拒稿，真的很快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 30 21:50:00 CST 2011, time=2011-08-30, status=1, ipAttribution=)]

2011-08-30 匿名用户

三天拒稿，真的很快！

341 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务